AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

TRISTEL PLC

Report Publication Announcement Apr 28, 2014

7990_rns_2014-04-28_2764262f-d69d-4d76-8eb5-76f1f84dc8fb.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6019F

Tristel PLC

28 April 2014

Tristel plc

("Tristel" or "the Company")

Trading Update

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, provides a trading update for the year ending 30 June 2014, showing results ahead of previously upgraded expectations.

Tristel addresses three distinct markets: Human Healthcare, Animal Healthcare and Contamination Control, with three distinctively branded product ranges: Tristel, Anistel and Crystel.

Tristel announced in its Interim Statement on 3 March 2014 that it had experienced a strong start to the second half across all areas of the business.  The Company is now confident that the momentum evident throughout the first half will continue through to the end of the financial year and beyond, resulting in pre-tax profit for the year to 30 June 2014 of no less than £1.5m (2013: £0.4m adjusted pre-tax profit*). This level of profit is ahead of current market expectations.  

The balance sheet continues to strengthen with cash balances exceeding £2.2m (£1.5m at 31 December 2013). 

Paul Swinney, Chief Executive, comments "The momentum that we have built since the beginning of 2013 is gathering pace both in the UK and overseas markets and across all three product portfolios. Over the past three years the business has undergone a transformation to focus upon innovative consumable products which are essential within the healthcare setting. One recent success has been our inclusion in the NHS Scotland framework agreement for surface disinfectant products." 

*Adjusted for non-recurring items of £2.2m

For further information please contact:        

## Tristel plc Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Finance Director
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07854 391 303
finnCap Tel: 020 7600 1658
Geoff Nash (Corporate Finance)
Charlotte Stranner (Corporate Finance)
Simon Starr (Corporate Broking)

This information is provided by RNS

The company news service from the London Stock Exchange

END

TSTDDLFLZZFFBBQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.